Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863798 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
NCT00863798 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 682 participants.
The verdict
NCT00863798, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.
Interventions
- DRUG placebo
- DRUG Desvenlafaxine Succinate Sustained-Release 10mg
- DRUG Desvenlafaxine Succinate Sustained-Release 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863798
The ClinicalTrials.gov registry entry for NCT00863798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00863798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863798 about?
NCT00863798 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder". The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of l...
What is the current status of trial NCT00863798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2009-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00863798?
The interventions under investigation include: placebo (DRUG), Desvenlafaxine Succinate Sustained-Release 10mg (DRUG), Desvenlafaxine Succinate Sustained-Release 50 mg (DRUG).
Who is sponsoring clinical trial NCT00863798?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.